Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Other

Pharmather enters obesity market with PharmaPatch

By The Northwire Desk — AI Analysis Jan 14, 2026 · 18:13 PHRM · 0.095 Pharmather Holdings Ltd
PHRM · Price

Executive Summary

  • Pharmather Holdings Ltd. is expanding its PharmaPatch microneedle patch platform to develop GLP-1 therapies for the potential treatment of obesity, leveraging prior progress in ketamine and psychedelic patch programs.
  • The company aims to create a needle-free, at-home microneedle patch capable of sustained, long-acting delivery of GLP-1 drugs, potentially supporting up to one month of exposure from a single application.
  • This strategic move targets a significant market opportunity, with the U.S. obesity treatment market estimated at $11.2 billion in 2024 and projected to reach $48.5 billion by 2030.

Key Details

  • Platform Expansion: The initiative applies Pharmather’s existing microneedle patch technology—previously used for ketamine and psychedelic compounds—to GLP-1 therapies.
  • Product Features: The proposed GLP-1 PharmaPatch offers needle-free intradermal delivery, at-home convenience, and flexible dosing via patch design variables (surface area, application time, drug loading).
  • Delivery Profile: The goal is sustained, controlled delivery with a potential duration of up to one month per single patch application, subject to formulation optimization and clinical validation.
  • Market Context: The expansion addresses major public health challenges, citing CDC data that over two in five U.S. adults have obesity.
  • Development Status: The company is currently progressing through feasibility work and preclinical evaluation.
  • Intellectual Property: Pharmather is finalizing a patent application covering innovations from this program and expects to file it later this month.

Notable Quotes

  • "Pharmather built PharmaPatch to solve real-world administration challenges delivering medicines in a patient-friendly form factor with the potential to support sustained drug exposure... Our objective is to develop a needle-free, at-home microneedle patch designed to support long-acting delivery -- potentially up to one month from a single patch application." — Fabio Chianelli, Founder and CEO
Read the original news release →

More from Pharmather Holdings Ltd

May 27, 2026 · 08:01

PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

Other May 13, 2026 · 10:12

PharmaTher Explores Hantavirus Treatment Amidst Stock Plunge and Strategic Pivots

Other May 13, 2026 · 10:08

PharmaTher Advances Antiviral Pipeline with Hantavirus Candidate Amidst Ketamine Monetization

Other Apr 21, 2026 · 08:01

Strategic Alignment with Federal Psychedelic Mandate

Regulatory Apr 20, 2026 · 08:01

PharmaTher Seeks Regulatory Tailwinds Amidst Price Slump

Production / Operations Apr 16, 2026 · 08:01

PharmaTher Peptide Strategy Faces Regulatory Hurdles Amidst 89% Stock Decline

Regulatory